Over the past decade, our understanding of inflammatory demyelinating conditions has expanded dramatically. As clinicians have gained better diagnostic tools and clearer criteria two conditions similar to multiple sclerosis, Neuromyelitis Optica Spectrum Disorders (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD), are now recognised as distinct autoimmune disorders. Receiving the right information about a diagnosis and management strategies can be lifechanging.
To support this Multiple Sclerosis New Zealand has developed new webpages on both NMOSD and MOGAD. Here, we introduce these conditions and explain why awareness is so important for the wider MS community.
A closer look at NMOSD
NMOSD is an autoimmune condition that primarily targets the optic nerves and spinal cord, and occasionally specific areas of the brain. Many people with NMOSD have a particular antibody known as AQP4IgG (“aquaporin-4”), which has become a key indicator in confirming the diagnosis. Although attacks can resemble those seen in MS, NMOSD behaves differently and requires its own approach to treatment and long-term care.
Symptoms often appear rapidly and may begin with blurred or reduced vision, pain with eye movement, or significant vision loss. Others may notice weakness in their arms or legs, difficulty walking, or unusual sensations such as tingling or burning. Some people experience persistent nausea or hiccups due to inflammation in a small but important part of the brainstem. Because NMOSD attacks can be severe and may lead to long-term disability, early medical attention is vital.
Diagnosis typically involves a combination of neurologist assessment of symptoms, MRI imaging, eye assessments, and specific antibody testing. Treatment during an attack generally includes high dose intravenous steroids, sometimes followed by plasma exchange. Long-term treatment focuses on reducing the risk of further relapses and may involve immune modifying therapies alongside supportive care such as physiotherapy, occupational therapy, and vision rehabilitation. Regular monitoring is important, particularly for people taking medications that affect immune function.
Understanding MOGAD
While MOGAD can look like NMOSD and MS at first glance, it arises from a distinct autoimmune response targeting a protein called MOG, found on the surface of certain nerve cells. The most common early sign is optic neuritis, which may cause blurry or cloudy vision, pain when moving the eyes, or colours appearing faded. Some people may develop weakness, numbness, or difficulty walking.
Diagnosis includes neurologist assessment of symptoms, specialised MOGIgG blood test, MRI scans of the brain, optic nerves, and spinal cord. As with NMOSD, early treatment is important. Most people respond quickly to high-dose steroids, and some may require plasma exchange or IVIg. Not everyone with MOGAD will experience further relapses, but for those who do, long-term therapies are available to help reduce attack frequency. Ongoing monitoring and tailored rehabilitation can support recovery and help people return to everyday life.
Why Greater Awareness Matters
NMOSD and MOGAD sit alongside MS in the family of demyelinating conditions. For many people, the journey begins with symptoms that look like MS and, while there are distinct differences, there are many similarities in the interventions and support needed for people to live well with these long-term conditions. This is why Multiple Sclerosis NZ feel it’s important that people have access to clear, accurate, and up-to-date information from us regarding NMOSD and MOGAD.
Internationally, there is now a strong shift toward recognising NMOSD and MOGAD within the broader landscape of MS advocacy and policy work. The MS Brain Health initiative has expanded its global recommendations to explicitly include NMOSD and MOGAD, emphasising timely diagnosis, early treatment, and equitable access to care across all three conditions. Likewise, MS Australia has integrated NMOSD and MOGAD into its national advocacy and research agenda, acknowledging that progress in understanding one demyelinating condition supports breakthroughs across the entire neuroimmune spectrum.
These global movements highlight a growing recognition that people living with NMOSD and MOGAD face many of the same challenges as those living with MS, diagnostic uncertainty, limited treatment access, and the need for coordinated, specialist care. By aligning NMOSD and MOGAD more closely with established MS advocacy frameworks, international organisations are strengthening the visibility of these conditions and improving the support available for everyone affected.
Learn More
In response to this, MSNZ has developed new webpages that provide easy to understand information on both NMOSD and MOGAD. These pages cover symptoms, diagnosis, and an overview of treatment options, and links to trusted information sources.
We encourage those who want to know more to explore the new pages and share them within their networks. Strengthening understanding across our community helps ensure that every person navigating these conditions feels informed, supported, and connected.